

L-Carnitine

(Hypoallergenic)



Item # 70640 (250 mg) 40 tablets

Item # 73930 (500 mg) 250 tablets

The Possible Benefits of L-Carnitine, a Dietary Supplement

- Supports the body's ability to convert fatty acids to cellular energy*
- Supports healthy circulation, the heart and cardiovascular system*
- May support healthy fat metabolism in the liver*

Description

L-Carnitine is an amino acid found in most of the body's cells, where it transports long-chain fatty acids in the mitochondria, a key step in the production of cellular energy (ATP). The liver manufactures L-carnitine from L-lysine and L-methionine, requiring niacin, iron, and vitamins B6 and C in the process. L-carnitine is considered "conditionally essential", especially during times of high energy needs, such as pregnancy and breast-feeding.*

L-carnitine supports healthy circulation and the cardiovascular system, enhancing cardiac function and helping to protect the heart.* It supports triglycerides within normal levels, HDL-cholesterol within normal levels, and has antioxidant properties.*

The body stores most of its L-carnitine in cardiac and skeletal muscles. Cardiac and skeletal muscles rely on the beta-oxidation

of long-chain fatty acids for a significant portion of their cellular energy. This process of releasing energy from fat utilizes L-carnitine to transport the fatty acids across the inner membrane of the mitochondria. L-carnitine also helps remove accumulations of short- and medium-chain fatty acids from the mitochondria, as well as enhance the utilization of pyruvate and the efficiency of oxidative phosphorylation.* Together these functions facilitate cellular energy production.*

When utilized along with an exercise program, L-carnitine can reduce muscle soreness after exercising, and may support positive changes in metabolism and un-toned muscles.* L-carnitine may also support healthy fat metabolism in the liver.* L-carnitine does not provide the neuroprotective activity of acetyl-L-carnitine.*

Serving Size: 1 tablet

Servings Per Container: 40 (#70640) and 250 (#73930)

Amount Per Serving:

L-Carnitine (#70640) 250 mg

L-Carnitine (#73930) 500 mg

Other ingredients:

Cellulose, dicalcium phosphate, silicon dioxide, magnesium stearate, stearic acid.

Suggested Use: As a dietary supplement, 1 to 4 tablets (Item #70640), or 1 or 2 tablets (Item #73930) daily with meals, or as directed by a healthcare practitioner.

*THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION. THIS PRODUCT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE.

References:

- Anand I, Chandrashenkhan Y, De Giuli F, et al. *Cardiovasc Drugs Ther* 1998;12:291-9.
- Bohles H, Richter K, Wagner-Thiesson E, Schafer H. *Eur J Pediatr*. 1982; 139:185-186.
- Bohmer T, Rynding A, Solberg HE. *Clin Chim Acta*. 1974; 57:55-61.
- Borum PR. Carnitine. *Ann Rev Nutr*. 1983; 3:233-259.
- Brevetti G, Chiarello M, Ferulano G, et al. *Circul*. 1988; 77:767-773.
- Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. *J Am Coll Cardiol*. 1999; 35:1618-1624.
- Brooks H, Goldberg L, Holland R, et al. *J Clin Pharmacol*. 1977; 17:561-578.
- Christiansen R, Bremer J. *Biochem Biophys Acta*. 1977; 448:562-577.
- Columbani P, Wenk C, Kunz I, et al. *Eur J Appl Physiol* 1996;73:434-9.
- Dal Negro R, Pomari G, Zoccatelli O, Turco P. *Int J Clin Pharmacol Ther Toxicol* 1986;24:453-6.
- Dal Negro R, Turco P, Pomari C, De Conti F. *Int J Clin Pharmacol Ther Toxicol* 1988;26:269-72.
- de Simone C, Famularo G, Tzantzoglov S, et al. *AIDS*. 1994; 8:655-660.
- Del Favero A. *Lancet* 1988;2:337 [letter].
- Digiesi V, Palchetti R, Cantini F. *Minerva Med* 1989;80:227-31.
- Dipalma JR. *Am Fam Physician* 1988;38:243-51.
- Giamberardino MA, Dragani L, Valente R, et al. *Int J Sports Med* 1996;17:320-4.
- Giovannini M, Agostoni C, Salari PC. *J Int Med Res* 1991;19:88-102.
- Green RE, Levine AM, Gunning MJ. *J Am Diet Assoc* 1997;(suppl):A-72.
- Kendler BS. *Prev Med* 1986;15:373-90.
- Kobayashi A, Masumura Y, Yamazaki N. *Jpn Circ J* 1992;56:86-94.
- Lindstedt S, Lindstedt G. *Acta Chim Scand*. 1961; 15:701-702.
- Maebashi M, Kawamura N, Sato M, et al. *Lancet*. 1978; 2:805-807.
- Mancini M, Rengo F, Lingetti M, et al. Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. *Arzneimittelforschung* 1992;42:1101-4.
- Marzo A, Arrigoni Martelli E, Mancinelli A, et al. *Eur J Drug Met Pharmacokin Special Issue III*. 1992; 364-368.
- Murray MT. *Am J Natural Med* 1996;3:6-14 [review].
- Nezu J, Tamai I, Oku A, et al. *Nat Gen*. 1999; 21:91-94.
- Opie LH. *Am Heart J*. 1979; 97:375-388.
- Pola P, Savi L, Grilli M, et al. *Curr Therapeu Res*. 1980; 27:208-216.
- Prockup LD, Engel WK, Shug AL. *Neurol*. 1983; 33:1629-1631.
- Rebouche CJ, Engel AG. *Mayo Clin Proc*. 1983; 58:533-540.
- Rebouche CJ, Paulson DJ. *Ann Rev Nutr*. 1986; 6:41-68.
- Rebouche CJ. *FASEB J*. 1992; 6:3379-3386.
- Rossi CS, Siliprandi N. *Johns Hopkins Medical J*. 1982; 150:51-54.
- Sachan DS, Rhew TH, Ruark RA. *Am J Clin Nutr*. 1984; 39:738-744.
- Tamamogullari N, Silig Y, Icagasioglu S, Atalay A. *J Diabetes Complications* 1999;13:251-3.
- Triggs WJ, Bohan TP, Shen-Nan L, Wilmore J. *Arch Neurol*. 1990; 47:1131-1133.
- Vacha GM, Giorcelli G, Siliprandi N, Corsi G. *Am J Clin Nutr*. 1983; 38:532-540.
- Yesilipek MA, Hazar V, Yegin O. *Acta Haematol* 1998;100:162-3.



Scientific Bo-Logics®

16612 Burke Lane - Huntington Beach
California - 92647 - Email: info@sblogics.com
Tel: 714-847-9355 - Fax: 714-848-8311
www.sblogics.com

*THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION. THIS PRODUCT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE.